Abstract2-Piperidone has been identified as a biomarker for various human diseases, but its originin vivoremains poorly understood. Furthermore, 2-piperidone is a crucial industrial raw material, and thus the discovery of novel efficient 2-piperidone synthases may have an important application in its biosynthesis. In this study, we aimed to identify the bacterial source and metabolic mechanism of 2-piperidone from a previously generated infant gut microbial culture collection. We found that 2-piperidone could be produced from 5AVA by four bacterial strains, includingCollinsella aerofaciensLFYP39,Collinsella intestinalisLFYP54,Clostridium bolteaeLFYP116, andClostridium hathewayiLFYP18 from 51 bacterial strains. Furthermore, 2-piperidone could be synthesized from proline by cross-feeding betweenClostridium difficileLFYP43 andCollinsella intestinalisLFYP54. We employed a gain-of-function library to identify the geneavaC(5-aminovaleric acid cyclase) which can catalyze 5AVA to produce 2-piperidone inC. intestinalisLFYP54. Homologous genes ofavaCwere also identified and validated in the other three bacterial strains. GeneavaCexhibits a broad distribution in the natural environmental bacteria. Overall, our research identified the gut bacterial strains and the genes that are responsible for the production of 2-piperidone. This study may facilitate the prediction of 2-piperidone-related disease risks through the analysis of gut bacterial community composition, and enhance the efficiency of 2-piperidone in its biosynthesis in industry.ImportanceIn recent decades, it has become a consensus that gut microbiota can affect host health through producing metabolites. However, the complexity of gut flora composition makes finding the sources of the particular metabolite challenging. 2-piperidone is a biomarker for various diseases and a highly valued raw material for nylons. In this study, we identified the gut bacterial strains that can transform 5AVA to 2-piperidone. A novel 2-piperidone synthase gene,avaC, was also identified and characterized. These findings provided new insights into the potential connection between 2-piperidone related diseases and the intestinal flora, as well as a possible novel approach for more efficient biosynthesis of 2-piperidone in industry.